Company Profile

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Employees

103

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 21:00:00 25/09/2025 BST			5-day change	1st Jan Change
3.390 ^USD	-.--%		-.--%	-

26/09/25	Theratechnologies Inc.(NasdaqCM:THTX) dropped from S&P Global BMI Index	CI
25/09/25	CB Biotechnology, LLC completed the acquisition of Theratechnologies Inc. (TSX:TH).	CI

26/09/25	Theratechnologies Inc.(NasdaqCM:THTX) dropped from S&P Global BMI Index	CI
25/09/25	CB Biotechnology, LLC completed the acquisition of Theratechnologies Inc. (TSX:TH).	CI
25/09/25	Theratechnologies Shares to Be Delisted From Nasdaq After Future Pak Finalizes Acquisition	MT
24/09/25	Theratechnologies Inc.(NasdaqCM:THTX) dropped from NASDAQ Composite Index	CI
22/09/25	Theratechnologies Inc.(NasdaqCM:THTX) added to S&P Global BMI Index	CI
16/09/25	Theratechnologies Gets Final Court Approval for Acquisition by Future Pak	MT
16/09/25	Theratechnologies receives final court approval on to be acquired by Future Pak	RE
12/09/25	Theratechnologies Shareholders Approve Acquisition by Future Pak	MT
12/09/25	Theratechnologies Inc. - Shareholder/Analyst Call
05/09/25	Theratechnologies Inc. Announces Availability of EGRIFTA WR (tesamorelin) for Injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy	CI
05/09/25	Theratechnologies Launches New Tesamorelin Formulation in US After FDA Approval	MT
05/09/25	Theratechnologies Brief: Announcing Availability Of EGRIFTA WR (Tesamorelin) For Injection To Reduce Excess Abdominal Fat In Adults With HIV And Lipodystrophy	MT
02/09/25	Theratechnologies Inc - ISS and Glass Lewis recommend voting 'for' Future PAK arrangement	RE

09/07/25	Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand	RE
03/07/25	JonesTrading Downgrades Theratechnologies to Hold From Buy	MT
17/07/23	JonesTrading Adjusts Price Target on Theratechnologies to $3 From $6, Maintains Buy Rating	MT
03/07/23	Canaccord Assumes Theratechnologies at Hold With $2 Price Target	MT
17/11/22	Cantor Fitzgerald Starts Theratechnologies at Overweight With $9 Price Target	MT

12-05	"A Change Is A Change" – The Supreme Court Rejects A Narrow Interpretation Of "Material Change"	AQ
25/09/25	Theratechnologies Announces Completion of Acquisition by Future Pak	AQ
16/09/25	Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak	AQ
12/09/25	Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak	AQ
05/09/25	Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy	AQ

Theratechnologies Inc. Share Price Nasdaq

Stocks

THTX

CA88338H7040

Pharmaceuticals

Chart: Theratechnologies Inc.

Latest news : Theratechnologies Inc.

Last Transcript: Theratechnologies Inc.

Analysts' recommendations: Theratechnologies Inc.

Press Releases: Theratechnologies Inc.

News in other languages: Theratechnologies Inc.

Course Extremes

Managers and Directors: Theratechnologies Inc.

Biopharmaceuticals

Company Profile

Income Statement and Estimates

09/07/25	Theratechnologies : FS Q2 2025 V6 FRE
09/07/25	Theratechnologies : MDA Q2 2025 V4 FRE
31/07/23	Theratechnologies réalise un regroupement d’actions à raison de 1 pour 4
28/07/23	Theratechnologies annonce des modifications à sa facilité de prêt à terme auprès de sociétés du même groupe que Marathon Asset Management
21/07/23	Theratechnologies annonce la démission de l’un de ses administrateurs, M. Gary Littlejohn

Manager	Title	Age	Since
Paul Lévesque CEO	Chief Executive Officer	62	05/04/2020
Philippe Dubuc DFI	Director of Finance/CFO	59	23/02/2016
Christian Marsolais CTO	Chief Tech/Sci/R&D Officer	63	31/12/2006

Director	Title	Age	Since
Dawn Svoronos CHM	Chairman	72	07/04/2013
Andrew Molson BRD	Director/Board Member	58	15/10/2020
Dale MacCandlish-Weil BRD	Director/Board Member	70	15/05/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERATECHNOLOGIES INC.	-.--%	-.--%	-	-	148M
REGENERON PHARMACEUTICALS, INC.	+4.07%	+8.45%	+25.67%	-2.34%	68.8B
UCB	-1.42%	-2.99%	+47.09%	+218.97%	55.21B
SAMSUNG BIOLOGICS CO.,LTD.	+1.21%	+42.20%	+42.20%	+42.20%	43.46B
CSL LIMITED	+0.27%	+8.33%	-49.87%	-53.43%	41.18B
MODERNA, INC.	-2.48%	+13.91%	+166.79%	-32.89%	31.65B
BIOGEN INC.	-1.32%	-4.79%	+58.07%	-25.22%	30.37B
INCYTE CORPORATION	+2.10%	+4.14%	+75.49%	+90.19%	23.58B
INNOVENT BIOLOGICS, INC.	-1.15%	+8.29%	+4.42%	+184.96%	19.33B
SWEDISH ORPHAN BIOVITRUM AB	-1.38%	+2.55%	+65.66%	+132.94%	17.16B
Average	+0.06%	+4.29%	+48.39%	+61.71%	36.75B
Weighted average by Cap.	+0.52%	+4.19%	+42.88%	+53.63%

1 year	3.14	3.4
3 years	0.88	3.92
5 years	0.88	17.84
10 years	0.88	45